Metastatic Pancreatic Cancer research hub
6 indexed studies · 3 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)
This study is looking into a new treatment, VCN-01, alongside standard chemotherapy for pancreatic cancer that has spread. It aims to see how well patients live and if the new treatment is safe and tolerable.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel
This study is testing a new medicine called IOA-289, given alongside standard chemotherapy (gemcitabine and nab-paclitaxel), for people with pancreatic cancer that has spread. It's an early-stage study to find the safest and most effective dose of IOA-289.
Italy - not yet recruitingPHASE1
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
This early-stage study is looking at a new, personalised vaccine treatment for advanced bowel or pancreatic cancer. It checks if the treatment is safe, possible to give, and if it helps control the cancer. Researchers are also figuring out the right dose.
France - recruitingPHASE2
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy
This study is testing a new way to use FOLFIRINOX, a chemotherapy drug combination, for people with pancreatic cancer that has spread or can't be removed by surgery. We want to see how well it works and if it's safe as a first treatment.
France - recruitingPHASE1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
This study is testing a new drug called IPH5301 for advanced cancers like breast, stomach, and lung. It's a first-time-in-human study, meaning it's the very first time this drug is being given to people. Researchers want to find a safe dose, either alone or with other treatments.
France - active not recruitingNA
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
This study is testing a new radiation treatment called DaRT for advanced pancreatic cancer. It involves placing small devices directly into the tumour to deliver radiation. Doctors want to see if it's safe and effective for people whose cancer can't be removed by surgery.
Canada